RxDoctor Payments Data

Rachel Best

Family · Alcoa, TNNPI 1710134499

Payments from drug & device makers

$784in general payments, 2019–2025

Across 31 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$165
  • Avanir Pharmaceuticals, Inc.$152
  • Neurocrine Biosciences, Inc.$55
  • Novo Nordisk$53
  • Eisai Inc.$51
  • Inspire Medical Systems, Inc.$47
  • plus $261 from 10 others

What the payments were for

  • Food & beverage$784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,100
Medicare patients
42
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$37,884
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$26,801
OzempicSemaglutide28$26,367
RybelsusSemaglutide14$20,462
JardianceEmpagliflozin11$10,677
TrulicityDulaglutide11$10,507
JanuviaSitagliptin Phosphate11$6,177
Albuterol Sulfate HfaAlbuterol Sulfate76$2,343
Tresiba Flextouch U-100Insulin Degludec12$2,132
Sertraline Hcl52$1,258
Potassium Chloride79$1,201
Fluticasone Propionate48$715
Atorvastatin Calcium93$710
Duloxetine Hcl15$674
Pantoprazole Sodium45$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$53$46,82942 claims
GSKTrelegy Ellipta$23$26,80128 claims
Lilly USA, LLCTrulicity$23$10,50711 claims
AbbVieSynthroid$40$23413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →